Income StatementBalance SheetCash FlowSegments
Abbott logo

Abbott Business Segments

Business, geographic, and product segment breakdowns

Abbott generates $45.1B in annual revenue across 4 key segments: Diagnostic Products ($9.1B), Established Pharmaceuticals ($5.7B), Medical Devices ($22.0B), and Nutritional Products ($8.3B). The company-wide operating margin is 17.07%. Based on the Q1 2026 filing.

Diagnostic Products (TTM)$9.1BEstablished Pharmaceuticals (TTM)$5.7BMedical Devices (TTM)$22.0BNutritional Products (TTM)$8.3B
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$152.25B
P/E Ratio24.26
ROE12.44%

Geographic

Net Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
International$6.6B$6.2B$6.9B$7.1B$7.1B$6.9B
United States$4.3B$4.2B$4.3B$4.3B$4.4B$4.3B
All Other Countries$3.7B$4.0B$4.0B$4.0B$4.0B—
China$528.3M$476.8M$476.8M$476.8M$476.8M—
Germany$634.8M$689.8M$689.8M$689.8M$689.8M—
India$454.3M$467.8M$467.8M$467.8M$467.8M—
Japan$360.3M$368.8M$368.8M$368.8M$368.8M—
Switzerland$436.8M$467.8M$467.8M$467.8M$467.8M—
United Kingdom$296.3M$335.0M$335.0M$335.0M$335.0M—

Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Non-US$0.0———$0.0—
United States$10.3B———$11.9B—

Business Segments

Additions to Property and Equipment

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$186.0M$156.0M$145.0M$140.0M$217.0M$147.0M
Diagnostic Products$283.0M$135.0M$166.0M$168.0M$292.0M$128.0M
Nutritional Products$100.0M$79.0M$81.0M$71.0M$71.0M$40.0M
Established Pharmaceuticals$65.0M$33.0M$39.0M$38.0M$59.0M$20.0M

Cost of products sold, excluding amortization of intangible assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices-$11.2B$1.6B$1.8B$1.8B-$12.1B$1.8B
Diagnostic Products-$8.7B$1.2B$1.2B$1.3B-$8.7B$1.2B
Nutritional Products-$7.9B$1.1B$1.2B$1.2B-$8.1B$1.1B
Established Pharmaceuticals-$4.3B$569.0M$631.0M$714.0M-$4.5B$644.0M

Depreciation

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostic Products$134.0M$126.0M$135.0M$136.0M$136.0M$144.0M
Medical Devices$82.0M$88.0M$94.0M$97.0M$99.0M$100.0M
Nutritional Products$43.0M$42.0M$44.0M$47.0M$42.0M$50.0M
Established Pharmaceuticals$25.0M$23.0M$25.0M$28.0M$25.0M$30.0M

Goodwill, non-deductible

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$16.8B$16.9B$17.3B$17.4B$17.4B$17.3B
Diagnostic Products$3.5B$3.5B$3.6B$3.6B$3.6B$14.9B
Established Pharmaceuticals$2.6B$2.6B$2.7B$2.7B$2.7B$2.7B
Nutritional Products$285.0M$285.0M$285.0M$285.0M$285.0M$300.0M

Net Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$5.1B$4.9B$5.4B$5.4B$5.7B$5.5B
Diagnostic Products$2.5B$2.1B$2.2B$2.3B$2.5B$2.2B
Nutritional Products$2.1B$2.1B$2.2B$2.2B$1.9B$2.0B
Established Pharmaceuticals$1.3B$1.3B$1.4B$1.5B$1.4B$1.4B

Operating Earnings

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$1.8B$1.6B$1.8B$1.8B$2.0B$1.9B
Established Pharmaceuticals$271.0M$298.0M$346.0M$391.0M$255.0M$365.0M
Diagnostic Products$611.0M$359.0M$372.0M$400.0M$609.0M$335.0M
Nutritional Products$443.0M$394.0M$418.0M$360.0M$386.0M$311.0M

Remaining performance obligations

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostic Products$5.5B$5.7B$5.9B$6.0B$6.1B$6.2B
Medical Devices$440.0M$423.0M$427.0M$436.0M$444.0M$429.0M

R&D

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$391.0M$401.0M$430.0M$462.0M$460.0M$444.0M
Diagnostic Products$174.0M$151.0M$154.0M$150.0M$147.0M$155.0M
Nutritional Products$51.0M$52.0M$54.0M$55.0M$52.0M$54.0M
Established Pharmaceuticals$45.0M$42.0M$43.0M$42.0M$49.0M$41.0M

Selling, general, and administrative

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$1.3B$1.3B$1.4B$1.4B$1.4B$1.4B
Nutritional Products$490.0M$576.0M$585.0M$515.0M$435.0M$563.0M
Diagnostic Products$411.0M$392.0M$423.0M$413.0M$383.0M$448.0M
Established Pharmaceuticals$327.0M$351.0M$363.0M$364.0M$377.0M$376.0M

Total Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices$9.5B$10.0B$10.6B$10.6B$10.7B$11.0B
Diagnostic Products$7.7B$7.8B$8.2B$8.2B$8.3B$9.6B
Nutritional Products$4.4B$4.6B$4.9B$4.9B$4.8B$4.9B
Established Pharmaceuticals$3.1B$3.4B$3.7B$3.7B$3.5B$3.7B

Increase (decrease) in in-process research and development assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical Devices-$9.8M$107.0M$107.0M$107.0M$107.0M—